Finanzas de Dare Bioscience Inc (DARE)DAREDare Bioscience Inc

Evaluating the bottom line, Dare Bioscience Inc maintains a gross margin of -70.57%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1582.53%, while the net margin is -1590.42%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively DARE converts its operational activities into shareholder value.

In the context of the broader market, DARE competes directly with industry leaders such as ALLR and BFRI. With a market capitalization of $12.64M, it holds a significant position in the sector. When comparing efficiency, DARE's gross margin of -70.57% stands against ALLR's 100.00% and BFRI's 79.92%. Such benchmarking helps identify whether Dare Bioscience Inc is trading at a premium or discount relative to its financial performance.

Dare Bioscience has reported a significant decline in revenue, with Q1 2026 revenue at $15.45M, down 39.2% year-over-year. The company has also shown a negative net income of -$2.99M for Q1 2026, reflecting ongoing financial struggles.